In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
410 News Items found
MSK Chief Scientific Officer Dr. Ross Levine smiles at a trainee in the lab
MSK’s New Chief Scientific Officer, Dr. Ross Levine, on the Future of Cancer Research and Treatment

Learn more about MSK's new Chief Scientific Officer, Dr. Ross Levine, who has dedicated more than 25 years to studying blood and bone marrow cancers: “I believe there has never been a more exciting time for cancer science.”
Left-handed and right-handed KRas molecules
In the Lab
Mirror-Image Chemistry Enables New Approach for Targeting an “Undruggable” Cancer-Causing Protein

MSK chemists are focusing on developing small-molecule drugs to target KRas, an important cancer protein.
American Association for Cancer Research
AACR Virtual Meeting: COVID-19 and Cancer: Physician-in-Chief Lisa DeAngelis Featured on Forum About Getting Patients Back to the Clinic

Physician-in-Chief Lisa M. DeAngelis joins healthcare experts during the AACR Virtual Meeting: COVID-19 and Cancer to discuss how to safely bring patients to the clinic so they can receive vital cancer screenings and care.
Pictured: Filippo Giancotti
In the Lab
Researchers Shed Light on Why Some Breast Cancers Spread to the Lungs

A new Memorial Sloan Kettering study has identified one of the proteins fueling the spread of some breast cancers, and researchers hope their findings will lead to the development of new diagnostic tools and drugs.
Close up of microscope viewer.
Article
MSK Research Highlights, October 15, 2024

New MSK research identifies a gene mutation associated with resistance to breast cancer treatment; reports encouraging results for expanding use of a new prostate cancer radiotherapy; determines the best radiation level for avoiding complications treating spinal tumors; and finds that proton therapy is effective against previously treated head and neck cancers.
An MSK researcher at work in the lab
MSK Research Highlights August 31, 2026

New MSK research identifies a tumor-secreted protein that primes the lungs for metastasis; shows how a new drug combination improves survival in patients with advanced clear cell renal cell carcinoma; and find a three-drug combination works in most patients newly diagnosed with follicular lymphoma.
Nathanael Gray, Joshua Mendell, and Christopher Vakoc
Announcement
Three Scientists Are Named Winners of the Paul Marks Prize for Cancer Research

Memorial Sloan Kettering has named three winners of this year’s Paul Marks Prize for Cancer Research, an award that recognizes promising investigators.
Memorial Sloan Kettering Among the Top “Best Hospitals” for Cancer Care and Ranked First in Gynecology by U.S News & World Report

Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the rankings 30 years ago, MSK has held either the first or second spot each year for cancer care. MSK was also ranked first in gynecology.
Paul Marks Prize 2021 winners
Twenty Years Of Honoring A Legacy: Three Investigators Named Winners of Memorial Sloan Kettering Cancer Center’s 2021 Paul Marks Prize for Cancer Research

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.
Dana Pe'er and Scott Lowe
Expansion of Cell-to-Cell Communication Drives the Early Development of Pancreatic Cancer, New Research in Mice Finds

New MSK research combined sophisticated genetically engineered mouse models and advanced computational methods to map the earliest cell states leading to pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.